Nektar Therapeutics Presents First Preclinical Data On NKTR-0165 For Treatment Of Inflammatory Diseases At EULAR 2024
Portfolio Pulse from Benzinga Newsdesk
Nektar Therapeutics has presented preclinical data on NKTR-0165, a treatment for inflammatory diseases, at EULAR 2024. The data shows selective enhancement of Treg cell function through a novel mechanism. IND-enabling studies are underway, with first-in-human studies planned for the first half of 2025.
June 12, 2024 | 1:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nektar Therapeutics presented promising preclinical data on NKTR-0165, showing selective enhancement of Treg cell function. IND-enabling studies are in progress, with first-in-human studies expected in H1 2025.
The presentation of promising preclinical data and the announcement of upcoming first-in-human studies are positive indicators for Nektar Therapeutics. This could lead to increased investor confidence and a potential short-term boost in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100